Scotland backs Roche’s Rozlytrek for ROS1 lung cancerThe Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of Share XScotland backs Roche’s Rozlytrek for ROS1 lung cancerhttps://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
IL-6 drugs do work in COVID-19, says UK, as it plans NHS useNew data means that IL-6 drugs from Roche and Sanofi that had been all-but written off as coronavirus Share XIL-6 drugs do work in COVID-19, says UK, as it plans NHS usehttps://pharmaphorum.com/news/il-6-drugs-covid-19-new-trial/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
Roche set to file ophthalmology drug faricimab in DMERoche looks set to mount a challenge to Bayer’s ophthalmology drug Eylea in 2021 after its faricimab antibody Share XRoche set to file ophthalmology drug faricimab in DMEhttps://pharmaphorum.com/news/roche-set-to-file-ophthalmology-drug-faricimab-in-dme/
Roche claims EU okay for Herceptin/Perjeta combination PhesgoRoche has secured EU approval for Phesgo, a fixed-dose combination of its breast cancer drugs Herceptin and Perjeta Share XRoche claims EU okay for Herceptin/Perjeta combination Phesgohttps://pharmaphorum.com/news/roches-claims-eu-okay-for-herceptin-perjeta-combination-phesgo/
EUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedUK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 Share XEUSA Pharma hopes IL-6 drug will succeed in COVID-19 where rivals failedhttps://pharmaphorum.com/news/eusa-pharma-hopes-il-6-drug-will-work-in-covid-19-where-class-rivals-failed/
TG Therapeutics challenges Roche with FDA filing for CLL drugUS biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic Share XTG Therapeutics challenges Roche with FDA filing for CLL drughttps://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/
Roche, Blueprint raise pressure on Lilly with new Gavreto approvalThe FDA has cleared Roche and Blueprint Medicine’s Gavreto for a new use in RET-mutated thyroid cancer, putting Share XRoche, Blueprint raise pressure on Lilly with new Gavreto approvalhttps://pharmaphorum.com/news/roche-blueprint-raise-pressure-on-lilly-with-new-gavreto-approval/
